Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ELVN Enliven Therapeutics	$22.66 -2.9%	$20.02	$13.30 ▼ $30.03	$1.15B	0.83	306,262 shs	349,364 shs
PTCT PTC Therapeutics	$47.63 -1.9%	$48.83	$29.02 ▼ $58.38	$3.85B	0.5	875,491 shs	628,561 shs
RARE Ultragenyx Pharmaceutical	$26.31 -4.0%	$35.65	$26.00 ▼ $60.37	$2.59B	0.26	976,201 shs	3.90 million shs
ZLAB Zai Lab	$33.57 -6.8%	$34.64	$16.01 ▼ $44.34	$4.00B	0.99	917,358 shs	858,756 shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ELVN Enliven Therapeutics	-2.91%	+0.94%	+5.05%	+37.08%	-4.63%
PTCT PTC Therapeutics	-1.85%	-1.89%	-5.55%	+0.51%	+39.31%
RARE Ultragenyx Pharmaceutical	-4.01%	-10.84%	-29.56%	-26.28%	-40.05%
ZLAB Zai Lab	-6.78%	+2.57%	-9.10%	+16.40%	+79.14%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ELVN Enliven Therapeutics	2.8585 of 5 stars	3.5	2.0	0.0	2.6	4.2	0.0
PTCT PTC Therapeutics	4.4424 of 5 stars	4.3	1.0	4.4	2.8	0.8	1.3
RARE Ultragenyx Pharmaceutical	4.3772 of 5 stars	4.5	1.0	3.8	2.2	2.5	0.6
ZLAB Zai Lab	3.3156 of 5 stars	3.4	5.0	0.0	2.9	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ELVN Enliven Therapeutics	3.00	Buy	$41.20	81.82% Upside
PTCT PTC Therapeutics	2.67	Moderate Buy	$65.00	36.47% Upside
RARE Ultragenyx Pharmaceutical	2.93	Moderate Buy	$83.64	217.91% Upside
ZLAB Zai Lab	2.80	Moderate Buy	$54.28	61.68% Upside

Current Analyst Ratings Breakdown

Latest ELVN, ZLAB, PTCT, and RARE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/14/2025	RARE Ultragenyx Pharmaceutical	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$35.00 ➝ $34.00
7/14/2025	RARE Ultragenyx Pharmaceutical	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$65.00 ➝ $55.00
7/10/2025	RARE Ultragenyx Pharmaceutical	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$88.00 ➝ $65.00
7/2/2025	ELVN Enliven Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$40.00 ➝ $48.00
6/30/2025	ZLAB Zai Lab	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$73.00 ➝ $75.00
6/20/2025	RARE Ultragenyx Pharmaceutical	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$64.00
6/17/2025	PTCT PTC Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$80.00
6/16/2025	ELVN Enliven Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$40.00 ➝ $52.00
6/16/2025	ELVN Enliven Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$37.00
5/28/2025	RARE Ultragenyx Pharmaceutical	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$65.00
5/27/2025	PTCT PTC Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$68.00 ➝ $74.00

(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	$6.34 per share	N/A
PTCT PTC Therapeutics	$1.77B	2.13	N/A	N/A	($14.24) per share	-3.34
RARE Ultragenyx Pharmaceutical	$560.23M	4.44	N/A	N/A	$2.76 per share	9.53
ZLAB Zai Lab	$398.99M	9.35	N/A	N/A	$7.68 per share	4.37

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ELVN Enliven Therapeutics	-$89.02M	-$1.92	N/A	N/A	N/A	N/A	-31.84%	-30.09%	8/12/2025 (Estimated)
PTCT PTC Therapeutics	-$363.30M	$6.51	7.32	N/A	N/A	33.56%	-78.56%	32.11%	8/6/2025 (Estimated)
RARE Ultragenyx Pharmaceutical	-$569.18M	-$5.88	N/A	N/A	N/A	-93.04%	-186.49%	-36.81%	7/30/2025 (Estimated)
ZLAB Zai Lab	-$257.10M	-$2.49	N/A	N/A	N/A	-60.26%	-33.35%	-23.28%	8/7/2025 (Estimated)

Latest ELVN, ZLAB, PTCT, and RARE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	PTCT PTC Therapeutics	-$1.07	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	ELVN Enliven Therapeutics	-$0.54	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	RARE Ultragenyx Pharmaceutical	-$1.27	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	ZLAB Zai Lab	-$0.42	N/A	N/A	N/A	$125.66 million	N/A
5/14/2025	Q1 2025	ELVN Enliven Therapeutics	-$0.51	-$0.57	-$0.06	-$0.57	N/A	N/A
5/8/2025	Q1 2025	ZLAB Zai Lab	-$0.50	-$0.45	+$0.05	-$0.45	$118.40 million	$106.49 million
5/6/2025	Q1 2025	PTCT PTC Therapeutics	$0.85	$10.04	+$9.19	N/A	$437.16 million	$1.18 billion
5/6/2025	Q1 2025	RARE Ultragenyx Pharmaceutical	-$1.54	-$1.57	-$0.03	-$1.57	$145.98 million	$139.29 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	N/A
PTCT PTC Therapeutics	N/A	N/A	N/A	N/A	N/A
RARE Ultragenyx Pharmaceutical	N/A	N/A	N/A	N/A	N/A
ZLAB Zai Lab	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ELVN Enliven Therapeutics	N/A	21.07	21.06
PTCT PTC Therapeutics	N/A	3.89	3.85
RARE Ultragenyx Pharmaceutical	N/A	2.40	2.24
ZLAB Zai Lab	N/A	3.26	3.09

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ELVN Enliven Therapeutics	95.08%
PTCT PTC Therapeutics	N/A
RARE Ultragenyx Pharmaceutical	97.67%
ZLAB Zai Lab	41.65%

Insider Ownership

Company	Insider Ownership
ELVN Enliven Therapeutics	25.90%
PTCT PTC Therapeutics	5.50%
RARE Ultragenyx Pharmaceutical	5.50%
ZLAB Zai Lab	4.96%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ELVN Enliven Therapeutics	50	49.07 million	36.36 million	Optionable
PTCT PTC Therapeutics	1,410	79.26 million	74.90 million	Optionable
RARE Ultragenyx Pharmaceutical	1,294	94.54 million	89.34 million	Optionable
ZLAB Zai Lab	1,869	111.08 million	105.57 million	Optionable

ELVN, ZLAB, PTCT, and RARE Headlines

Recent News About These Companies

Zai Lab (NASDAQ:ZLAB) Shares Gap Down - Here's Why

July 18 at 12:04 PM | marketbeat.com

C WorldWide Group Holding A S Sells 40,000 Shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB)

July 18 at 10:27 AM | marketbeat.com

Marks Group Wealth Management Inc Invests $373,000 in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB)

July 14, 2025 | marketbeat.com

Alps Advisors Inc. Sells 12,097 Shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB)

July 12, 2025 | marketbeat.com

Zai Lab to Announce Second Quarter 2025 Financial Results and Recent Corporate Updates on August 7, 2025

July 10, 2025 | businesswire.com

Zai Lab (NASDAQ:ZLAB) Shares Gap Down - What's Next?

July 8, 2025 | marketbeat.com

67,159 Shares in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Bought by Penserra Capital Management LLC

July 8, 2025 | marketbeat.com

Principal Financial Group Inc. Purchases 1,121,856 Shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB)

July 5, 2025 | marketbeat.com

Ying Du Sells 7,072 Shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Stock

July 3, 2025 | marketbeat.com

Cantor Fitzgerald Lowers Earnings Estimates for Zai Lab

July 3, 2025 | marketbeat.com

Leerink Partnrs Analysts Lift Earnings Estimates for Zai Lab

July 2, 2025 | marketbeat.com

Insider Selling: Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) CEO Sells 6,918 Shares of Stock

July 2, 2025 | insidertrades.com

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) CEO Sells $245,727.36 in Stock

July 1, 2025 | marketbeat.com

Amgen and Zai Lab’s trial of gastric cancer therapy meets primary endpoint

July 1, 2025 | finance.yahoo.com

Amgen, Zai Lab succeed in gastric cancer study

June 30, 2025 | msn.com

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Given Consensus Recommendation of "Moderate Buy" by Analysts

June 30, 2025 | marketbeat.com

Zai Lab (NASDAQ:ZLAB) Price Target Raised to $75.00 at Leerink Partners

June 30, 2025 | marketbeat.com

Zai Lab (NASDAQ:ZLAB) Shares Gap Up - Still a Buy?

June 30, 2025 | marketbeat.com

Zai Lab Announces Positive Topline Phase 3 Results for Bemarituzumab in Fibroblast Growth Factor Receptor 2b (FGFR2b) Positive First-Line Gastric Cancer

June 30, 2025 | businesswire.com

Oppenheimer Asset Management Inc. Makes New Investment in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB)

June 30, 2025 | marketbeat.com

Zai Lab (ZLAB) chief legal officer sells $212k in shares

June 29, 2025 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELVN, ZLAB, PTCT, and RARE Company Descriptions

Enliven Therapeutics NASDAQ:ELVN

$22.66 -0.68 (-2.91%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$22.68 +0.02 (+0.09%)

As of 07/18/2025 04:20 PM Eastern

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

PTC Therapeutics NASDAQ:PTCT

$47.63 -0.90 (-1.85%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$47.62 -0.01 (-0.02%)

As of 07/18/2025 04:33 PM Eastern

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Ultragenyx Pharmaceutical NASDAQ:RARE

$26.31 -1.10 (-4.01%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$26.20 -0.11 (-0.42%)

As of 07/18/2025 07:56 PM Eastern

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

Zai Lab NASDAQ:ZLAB

$33.57 -2.44 (-6.78%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$34.01 +0.44 (+1.30%)

As of 07/18/2025 07:32 PM Eastern

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time